BB BIOTECH sells up to 2.6 mn shares to Deutsche Bank which will issue mandatory exchangeable bonds, exchangeable into such shares

5/14/2007, 7:30 AM (Source: GlobeNewswire)
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------



The Board of Directors of BB BIOTECH AG ("BB BIOTECH") has decided to
support the sale of BB BIOTECH shares by the company's wholly-owned
subsidiary BIOTECH Target N.V., via a structured equity disposal,
selling up to 2.6 mn BB BIOTECH shares to Deutsche Bank, which will
market a mandatory exchangeable into such shares as part of its
hedging strategy. Through this transaction the Board is continuing
its strategy of diversifying its shareholder base.

The Mandatory Exchangeable Bonds (the "Bonds") have an issue size of
up to CHF 250 mn, will be issued at 100 per cent of their principal
amount with a maturity of 5 years and an indicative coupon range of
2.5 - 3.0% (the "Offering"). The reference price will be the average
of the volume weighted average prices of the shares from May 14 to
May 15 2007. Deutsche Bank is acting as sole book runner and lead
manager in the Offering and Bank am Bellevue as co-lead manager.

Sale of shares to Deutsche Bank
The shares underlying the Bonds will be sold by BIOTECH Target N.V.
to Deutsche Bank. In order to fulfill this commitment, BIOTECH Target
N.V. will build up a short position in BB BIOTECH shares of up to 1.7
mn shares. The short position may later be covered by a capital
increase, particularly if shares of BB BIOTECH trade at a premium to
their NAV (Net Asset Value). Shares may also be purchased by BIOTECH
Target N.V. in the open market.

Placement
The Bonds will be allocated on May 14, 2007. The final terms will be
announced on May 15, 2007. Application will be made for the admission
of the Bonds to the Euro MTF Market of the Luxembourg Stock Exchange.
The Bonds will be offered to institutional investors only.

For further information please contact:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht,
Switzerland
Anja Stubenrauch or Dr. Christian Lach, Tel. +41 44 267 67 00

This press release is for information purposes only and is not an
offer to sell, or a solicitation of an offer to buy, any securities.
The distribution of this press release and the offer and sale of the
securities in certain jurisdictions may be restricted by law. Any
persons reading this press release should inform themselves of and
observe any such restrictions.
This press release is not an offer of securities for sale in the
United States. The offer and sale of the securities have not been,
and will not be, registered under the U.S. Securities Act of 1933, as
amended. The securities may not be offered or sold in the United
States or to U.S. persons absent such registration or an applicable
exemption from registration. There will be no offering of the
securities in the United States.

From the announcement of final terms of the issue of the Bonds,
Deutsche Bank AG and its agents may, to the extent permitted by and
in accordance with applicable laws and directives, effect
transactions with a view to supporting the market price of the Bonds
and the BB BIOTECH shares at a level higher than that which might
otherwise prevail for a limited period. Such stabilising, if
commenced, may be discontinued at any time and must be brought to an
end no later than the earlier of 30 days after the expected
settlement date and 60 days after the date of allotment of the Bonds.
If commenced, such stabilising may lead to a market price of the
Bonds or the BB BIOTECH shares which may be higher than the level
that would exist if no such stabilising measures were taken and may
indicate to the market a price stability which without such
stabilising might not prevail. However, there is no obligation on
Deutsche Bank to engage in such stabilisation activities.

Any offer made subsequently to this announcement is only addressed to
and directed at persons in member states of the European Economic
Area ("EEA") who are "qualified investors" within the meaning of
Article 2 (1) (e) of the Prospectus Directive (Directive 2003/71/EC)
("Qualified Investors")

Deutsche Bank is acting for its own account and for no one else in
connection with the Offering and will not be responsible to any
person for providing the protections afforded to clients of Deutsche
Bank nor for providing advice in relation to the Offering

The distribution of this announcement and the Offering in certain
jurisdictions may be restricted by law. No action has been taken by
Deutsche Bank or BB BIOTECH AG, or any of their representative
affiliates, that would permit an offer of bonds or possession or
distribution of this announcement or any other offering or publicity
material relating to such bonds in any jurisdiction where action for
that purpose is required. Persons into whose possession this
announcement comes are required by BB BIOTECH AG and Deutsche Bank to
inform themselves about and observe any such restrictions.



--- End of Message ---

BB BIOTECH AG
Vordergasse 3 Schaffhausen Switzerland

WKN: 888509;
ISIN: CH0001441580; Index: SBIOM, IGSP, SLIFE;
Listed: Investment Companies in SWX Swiss Exchange;
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.